(Reuters) - The U.S. Food and Drug Administration approved Biocryst Pharmaceuticals Inc's single-dose flu shot on Monday, for use in adults with acute uncomplicated influenza. The antiviral injection, peramivir, to be sold as Rapivab, inhibits the interactions of neuraminidase — an enzyme that is critical to the spread of influenza. The drug was developed under a $234.8 million contract from Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. (Reporting by Natalie Grover in Bengaluru; Editing by Joyjeet Das)
via Health News Headlines - Yahoo News http://ift.tt/1zUJPqp
via Health News Headlines - Yahoo News http://ift.tt/1zUJPqp
No comments:
Post a Comment